Belinda Sánchez Pérez

Belinda Sánchez Pérez

Auto-generated profile, based on publicly available information

Belinda Sánchez Pérez

H.R.U. Carlos Haya Málaga Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in World Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
BSBelinda Sánchez-Pérez
Belinda Sánchez-Pérez
Fast-track program in laparoscopic liver surgery: Theory or fact?

15 December 2021 in Perioperative Medicine
Verified
Journal Article
Open access
PDF file
JJJose Carlos Vilches Jimenez
Jose Carlos Vilches Jimenez
BSBeatriz Tripiana Serrano
Beatriz Tripiana Serrano
EMEmilia Villegas Muñoz
Emilia Villegas Muñoz
BPBelinda Sanchez Pérez
Belinda Sanchez Pérez
Jesus S Jimenez LopezJesus S Jimenez Lopez
Jesus S Jimenez Lopez
Background: Multimodal rehabilitation allows optimization of functional recovery in surgery patients by reducing the postoperative stress and hospital stay duration, without increasing the morbidity and mortality. It is reportedly successful in other surgical disciplines, and guidelines for its application to gynecological surgery are available; however, most evidence for these guidelines is derived from observational and/or retrospective studies. Therefore, this study aimed to investigate the applicability of an enhanced recovery after surgery (ERAS) protocol in laparoscopic gynecological surgery and its influence on the postoperative stay, morbidity, mortality, and readmission, through a prospective approach. Methods: This prospective cohort study was performed on 90 patients who underwent laparoscopic hysterectomy for benign causes from October 2017 to October 2019. Patients in whom the ERAS (ERAS group, n = 30) and traditional (control group, n = 60) protocols were implemented were compared. All patients were followed for 6 months. Results: The groups were homogeneous and did not differ significantly with respect to the demographic characteristics (age, ASA score, body mass index), surgical indications, and surgery types. Adherence to the ERAS protocol was over 99%. The postoperative hospital-stay durations were 1.73 days (r = 1–3) and 2.97 days (r = 2–6) in the ERAS and control groups, respectively (p = 0.000). No significant intergroup differences were observed in the rates of complications and readmissions. Conclusions: The ERAS protocol is applicable in laparoscopic gynecological surgery and can be implemented with good adherence. This can allow optimization of patient recovery by reducing the hospital stay duration, without increasing the rates of morbidity, mortality, or readmission.

31 October 2013 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
PRPedro C. Rodriguez
Pedro C. Rodriguez
BSBelinda Sanchez
Belinda Sanchez
This review is aimed to focus on NSCLC as an emerging and promising model for active immunotherapy and the challenges for its inclusion in the current clinical scenario. Cancer vaccines for NSCLC have been focused as a therapeutic option based on the identification of a tumor hallmark and the active immunization with the related molecules that triggers cellular and/or humoral responses that consequently destroy or delay the rate of malignant progression. This therapeutic intervention in an established disease state has been aimed to impact into prolonging patient´s survival with ethically accepted quality of life. Understanding of relationship between structure and function in cancer vaccines is essential to interpret their opportunities to impact into prolonging survival and increasing quality of life in cancer patients. It is widely accepted that the failure of the cancer vaccines in the NSCLC scenario is related with its introduction in the advanced disease stages and poor performance status of the patients due to the combination of the tumor induced immunosuppression with the immune senescence. Despite first, second and emerging third line of onco-specific treatments the life expectancy for NSCLC patients diagnosed at advanced stages is surrounding the 12 months of median survival and in facts the today real circumstances are extremely demanding for the success inclusion of cancer vaccines as therapeutic choice in the clinical scenario. The kinetics of the active immunizations encompasses a sequential cascade of clinical endpoints: starting by the activation of the immune system, followed by the antitumor response and finalizing with the consequential impact on patients’ overall survival. Today this cascade of clinical endpoints is the backbone for active immunization assessment and moreover the concept of cancer vaccines, applied in the NSCLC setting, is just evolving as a complex therapeutic strategy, in which the opportunities for cancer vaccines start from the selection of the target cancer hallmark, followed by the vaccine formulation and its platforms for immune potentiating, also cover the successful insertion in the standard of care, the chronic administration beyond progression disease, the personalization based on predictors of response and the potential combination with other targeted therapies.

17 March 2024 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
MRMaría Pérez Reyes
María Pérez Reyes
BPBelinda Sánchez Pérez
Belinda Sánchez Pérez
CGClaudia Sánchez González
Claudia Sánchez González
JDJosé Antonio Pérez Daga
José Antonio Pérez Daga
JVJulio Santoyo Villalba
Julio Santoyo Villalba
JSJulio Santoyo Santoyo
Julio Santoyo Santoyo

15 February 2024 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
BSBelinda Sánchez-Pérez
Belinda Sánchez-Pérez
JRJosé M Ramia
José M Ramia
Enhanced recovery after surgery (ERAS) programs have been widely applied in liver surgery since the publication of the first ERAS guidelines in 2016 and the new recommendations in 2022. Liver surgery is usually performed in oncological patients (liver metastasis, hepatocellular carcinoma, cholangiocarcinoma, etc. ), but the real impact of liver surgery ERAS programs in oncological outcomes is not clearly defined. Theoretical advantages of ERAS programs are: ERAS decreases postoperative complication rates and has been demonstrated a clear relationship between complications and oncological outcomes; a better and faster postoperative recovery should let oncologic teams begin chemotherapeutic regimens on time; prehabilitation and nutrition actions before surgery should also improve the performance status of the patients receiving chemotherapy. So, ERAS could be another way to improve our oncological results. We will discuss the literature about liver surgery ERAS focusing on its oncological implications and future investigations projects.

1 January 2020 in Nutrición Hospitalaria
Verified
Journal Article
Open access
CSCarmelo Loinaz Segurola
Carmelo Loinaz Segurola
FCFederico Ochando Cerdán
Federico Ochando Cerdán
ELEmilio Vicente López
Emilio Vicente López
ARAlejandro Serrablo Requejo
Alejandro Serrablo Requejo
PCPedro López Cillero
Pedro López Cillero
MSMiguel León Sanz
Miguel León Sanz
Revista oficial de la Sociedad Española de Nutrición Parenteral y de la Sociedad Española de Nutrición. Está dedicada al estudio y divulgación de temas relacionados con la nutrición.